vs
MESA LABORATORIES INC（MLAB）とFIRST FINANCIAL CORP（THFF）の財務データ比較。上の社名をクリックして会社を切り替えられます
FIRST FINANCIAL CORPの直近四半期売上が大きい（$70.5M vs $65.1M、MESA LABORATORIES INCの約1.1倍）。FIRST FINANCIAL CORPの純利益率が高く（30.4% vs 5.6%、差は24.8%）。FIRST FINANCIAL CORPの前年同期比売上増加率が高い（14.1% vs 3.6%）。FIRST FINANCIAL CORPの直近四半期フリーキャッシュフローが多い（$86.4M vs $18.0M）。過去8四半期でFIRST FINANCIAL CORPの売上複合成長率が高い（20.8% vs 5.1%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
ファーストアメリカン・ファイナンシャル・コーポレーションはアメリカの金融サービス企業で、不動産および住宅ローン業界向けに所有権保険と決済サービスを提供しており、関連分野で専門的なノウハウを蓄積した事業者です。
MLAB vs THFF — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $70.5M |
| 純利益 | $3.6M | $21.5M |
| 粗利率 | 64.2% | — |
| 営業利益率 | 12.2% | 37.4% |
| 純利益率 | 5.6% | 30.4% |
| 売上前年比 | 3.6% | 14.1% |
| 純利益前年比 | 316.6% | 32.1% |
| EPS（希薄化後） | $0.65 | $1.81 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $70.5M | ||
| Q3 25 | $60.7M | $65.8M | ||
| Q2 25 | $59.5M | $63.1M | ||
| Q1 25 | $62.1M | $62.5M | ||
| Q4 24 | $62.8M | $61.8M | ||
| Q3 24 | $57.8M | $58.4M | ||
| Q2 24 | $58.2M | $49.2M | ||
| Q1 24 | $58.9M | $48.4M |
| Q4 25 | $3.6M | $21.5M | ||
| Q3 25 | $2.5M | $20.8M | ||
| Q2 25 | $4.7M | $18.6M | ||
| Q1 25 | $-7.1M | $18.4M | ||
| Q4 24 | $-1.7M | $16.2M | ||
| Q3 24 | $3.4M | $8.7M | ||
| Q2 24 | $3.4M | $11.4M | ||
| Q1 24 | $-254.6M | $10.9M |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
| Q4 25 | 12.2% | 37.4% | ||
| Q3 25 | 7.8% | 39.2% | ||
| Q2 25 | 5.1% | 36.2% | ||
| Q1 25 | 2.4% | 38.1% | ||
| Q4 24 | 9.2% | 32.4% | ||
| Q3 24 | 6.1% | 17.9% | ||
| Q2 24 | 9.6% | 27.6% | ||
| Q1 24 | -460.6% | 27.2% |
| Q4 25 | 5.6% | 30.4% | ||
| Q3 25 | 4.1% | 31.6% | ||
| Q2 25 | 8.0% | 29.5% | ||
| Q1 25 | -11.4% | 29.5% | ||
| Q4 24 | -2.7% | 26.3% | ||
| Q3 24 | 5.9% | 15.0% | ||
| Q2 24 | 5.8% | 23.1% | ||
| Q1 24 | -432.2% | 22.6% |
| Q4 25 | $0.65 | $1.81 | ||
| Q3 25 | $0.45 | $1.75 | ||
| Q2 25 | $0.85 | $1.57 | ||
| Q1 25 | $-1.30 | $1.55 | ||
| Q4 24 | $-0.31 | $1.37 | ||
| Q3 24 | $0.63 | $0.74 | ||
| Q2 24 | $0.62 | $0.96 | ||
| Q1 24 | $-47.26 | $0.93 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | — |
| 総負債低いほど良い | $68.4M | $188.2M |
| 株主資本純資産 | $186.7M | $650.9M |
| 総資産 | $434.8M | $5.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 0.29× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | — | ||
| Q2 25 | $21.3M | — | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
| Q4 25 | $68.4M | $188.2M | ||
| Q3 25 | $69.4M | $170.5M | ||
| Q2 25 | $70.3M | $122.7M | ||
| Q1 25 | $71.3M | $124.9M | ||
| Q4 24 | $72.2M | $28.1M | ||
| Q3 24 | $73.1M | $30.5M | ||
| Q2 24 | $74.1M | $108.6M | ||
| Q1 24 | — | $58.6M |
| Q4 25 | $186.7M | $650.9M | ||
| Q3 25 | $178.5M | $622.2M | ||
| Q2 25 | $172.5M | $587.7M | ||
| Q1 25 | $159.8M | $571.9M | ||
| Q4 24 | $155.2M | $549.0M | ||
| Q3 24 | $161.5M | $566.0M | ||
| Q2 24 | $150.7M | $530.7M | ||
| Q1 24 | $145.4M | $520.8M |
| Q4 25 | $434.8M | $5.8B | ||
| Q3 25 | $430.4M | $5.7B | ||
| Q2 25 | $435.7M | $5.6B | ||
| Q1 25 | $433.3M | $5.5B | ||
| Q4 24 | $433.3M | $5.6B | ||
| Q3 24 | $454.1M | $5.5B | ||
| Q2 24 | $440.4M | $4.9B | ||
| Q1 24 | $446.8M | $4.9B |
| Q4 25 | 0.37× | 0.29× | ||
| Q3 25 | 0.39× | 0.27× | ||
| Q2 25 | 0.41× | 0.21× | ||
| Q1 25 | 0.45× | 0.22× | ||
| Q4 24 | 0.47× | 0.05× | ||
| Q3 24 | 0.45× | 0.05× | ||
| Q2 24 | 0.49× | 0.20× | ||
| Q1 24 | — | 0.11× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $90.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $86.4M |
| FCFマージンFCF / 売上 | 27.7% | 122.5% |
| 設備投資強度設備投資 / 売上 | 1.1% | 5.6% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 4.21× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $144.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $90.4M | ||
| Q3 25 | $8.2M | $26.9M | ||
| Q2 25 | $1.9M | $12.7M | ||
| Q1 25 | $12.7M | $21.1M | ||
| Q4 24 | $18.1M | $60.4M | ||
| Q3 24 | $5.3M | $23.3M | ||
| Q2 24 | $10.7M | $8.8M | ||
| Q1 24 | $12.9M | $12.4M |
| Q4 25 | $18.0M | $86.4M | ||
| Q3 25 | $7.1M | $25.8M | ||
| Q2 25 | $884.0K | $11.6M | ||
| Q1 25 | $11.9M | $20.5M | ||
| Q4 24 | $17.3M | $54.3M | ||
| Q3 24 | $3.5M | $19.5M | ||
| Q2 24 | $9.9M | $8.4M | ||
| Q1 24 | $12.3M | $11.5M |
| Q4 25 | 27.7% | 122.5% | ||
| Q3 25 | 11.7% | 39.2% | ||
| Q2 25 | 1.5% | 18.4% | ||
| Q1 25 | 19.2% | 32.8% | ||
| Q4 24 | 27.6% | 87.8% | ||
| Q3 24 | 6.0% | 33.5% | ||
| Q2 24 | 16.9% | 17.2% | ||
| Q1 24 | 21.0% | 23.7% |
| Q4 25 | 1.1% | 5.6% | ||
| Q3 25 | 1.8% | 1.7% | ||
| Q2 25 | 1.7% | 1.8% | ||
| Q1 25 | 1.2% | 0.9% | ||
| Q4 24 | 1.3% | 9.9% | ||
| Q3 24 | 3.1% | 6.5% | ||
| Q2 24 | 1.5% | 0.7% | ||
| Q1 24 | 0.9% | 2.0% |
| Q4 25 | 5.17× | 4.21× | ||
| Q3 25 | 3.32× | 1.29× | ||
| Q2 25 | 0.40× | 0.68× | ||
| Q1 25 | — | 1.14× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | 1.54× | 2.67× | ||
| Q2 24 | 3.17× | 0.77× | ||
| Q1 24 | — | 1.14× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
THFF
セグメントデータなし
